A health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese ...

Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time ...

A Japanese health ministry panel on Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese drugmaker Eisai Co. and US industry peer Biogen Inc., by 15 ...

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of ...

日本の製薬大手エーザイが共同開発したアルツハイマー病の治療薬「レカネマブ（Lecanemab）」が、米食品医薬品局（FDA）から正式承認された ...

Lecanemab may be safe and effective for treating early-stage Alzheimer’s disease within a small community of older adults, ...

Lecanemab’s PDUFA* date for its potential accelerated approval is January 6th. The product could launch after its approval by the Food and Drug Administration (FDA).

The US Food and Drug Administration has granted traditional approval to Eisai and Biogen’s Alzheimer’s therapy lecanemab, making the drug the first in its class to fully gain the green light ...

In a large study, experimental drug lecanemab was able to slow down Alzheimer's, but not stop it. Some researchers think the drug will become the first to help many patients; others have questions.

Lecanemab, the disease-modifying drug which can slow down the progression of Alzheimer’s disease, is set to be one of the most sought-after medications in the country after UK regulators ...

Lecanemab and Aduhelm are part of a class of drugs called monoclonal antibodies, and the agency that oversees Medicare has said it will only pay for this type of Alzheimer’s drug for patients ...